Global Single-use Bioprocessing Systems Market, By Product Type (Bioreactors, Bags and Containers, Filtration Devices, Tubing Assemblies and Connectors, Sensors and Probes and Others (Accessories & Consumables, etc.)), By Application (Monoclonal Antibody Production, Vaccine Production, Cell Therapy, Viral Vector Production, Gene Therapy and Other Biopharmaceutical Production Processes), By End User (Biopharmaceutical Companies, CROs & CMOs and Others (Research Labs & Institutes, etc.)) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa). Global single-use bioprocessing systems market was valued at US$ 35.19 Bn in 2024 and is expected to reach US$ 104.27 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 16.8% from 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Single-use bioprocessing systems are disposable technologies used in bioprocessing, which include disposable bioreactors, mixers, bags, tubing, connectors, sensors, and sampling systems. These systems find major application in the production of biologics, including monoclonal antibodies, hormones, vaccines, and gene therapy.
Global Single-use Bioprocessing Systems Market- Drivers
One of the major drivers for the growth of the global single-use bioprocessing systems market is the growing demand for cost-effective and flexible bioprocessing systems from biopharmaceutical manufacturers. Single-use bioprocessing systems offer significant cost savings over traditional stainless steel-based systems as they eliminate the need for cleaning and sterilization of equipment between batches. This reduces operational costs and time required for changeovers between product batches. Additionally, single-use bioprocessing systems are highly flexible, as they can be assembled quickly according to the production need and then disposed of after single use. This flexibility helps biomanufacturers to adapt production needs rapidly based on changing market demands. They no longer need to make large capital investments in fixed stainless steel-based production equipment or be constrained by their production capacity. The flexibility and reduced costs provided by single-use bioprocessing systems are highly appealing to biopharma companies, driving increased adoption. The use of single-use technologies allows for quicker production turnarounds, as manufacturers can easily switch between product pipelines within the same manufacturing facility. This helps accelerate drug development timelines and bring products to market faster. For instance, according to the UN Department of Economic and Social Affairs report (2020) monoclonal antibody therapies for cancer and immunological diseases doubled from 6 in 2011 to 12 in 2017. The pandemic has also underscored the need for resilient supply chains. Single-use technologies gave biopharma plants the agility to reconfigure production and redirect resources towards Covid vaccines and therapeutics.
Global Single-use Bioprocessing Systems Market - Restraints
One challenge restraining the growth of the market is the limited and difficult-to-find supply of trained personnel with expertise in single-use bioprocessing systems. While the systems offer several advantages, their design, assembly, operation, and validation processes differ from traditional stainless steel systems. This requires specialized training and skills that are not widely available yet. The novel nature of these systems and the different assembly procedures mean that there is a lack of experienced and trained professionals in the industry currently. This skills gap is making it difficult for some biopharma companies to smoothly implement single-use technologies at scale. It is also increasing their costs of procuring third-party experts until in-house talent pools can be sufficiently developed through training programs.
Global Single-use Bioprocessing Systems Market- Opportunities
Rising global demand for biologics and monoclonal antibody therapies to treat various chronic and life-threatening diseases acts as a key opportunity in the global single-use bioprocessing systems market. The development of novel biologics has increased hugely in recent years for indications like cancer, autoimmune disorders, and cardiovascular diseases. This growing pipeline of biologic drugs is fueling a significant demand for large-scale bioprocessing and production capabilities.
Single-use bioprocessing systems help biomanufacturers scale up production volumes efficiently and flexibly to meet this growing commercial demand. Their use across upstream and downstream processing allows for quicker production timelines at a lower cost. This factor is positively influencing the adoption of single-use bioprocessing systems for large-scale commercial production of in-demand biologics and monoclonal antibody therapies.
Global Single-use Bioprocessing Systems Market Segmentation:
The global single-use bioprocessing systems market report is segmented into product type, application, end user, and region.
Based on product type, the market is segmented bioreactors, bags and containers, filtration devices, tubing assemblies and connectors, sensors and probes, and others (accessories & consumables, etc.). Out of which, bioreactors contributes the highest share of the market owing to their increased efficiency and ability to process multiple batches simultaneously. Bioreactors, such as single-use stirred-tank bioreactors and wave bioreactors, allow for greater control over culture parameters like pH, temperature, oxygen levels and nutrition during cell culture processes. Their design also ensures optimum mixing and mass transfer, uniformly distributing nutrients to cells while removing waste. This enhances cell growth and productivity.
Based on application, the market is segmented into monoclonal antibody production, vaccine production, cell therapy, viral vector production, gene therapy, and other biopharmaceutical production processes. Out of which, monoclonal antibody production contributes the highest share of the market. Over the past decade, monoclonal antibody drugs have revolutionized the treatment of various chronic and life-threatening diseases, including cancer, rheumatoid arthritis, psoriasis, and more. As their clinical success and lucrative potential have been established, the demand as well as developmental pipeline for monoclonal antibody therapeutics are expanding at an exponential rate.
Based on end user, the market is segmented into biopharmaceutical companies, cros & cmos and others (research labs & institutes, etc.). Out of which, the biopharmaceutical companies contributes the highest share due to their extensive synergy with CMOs and flexibility needs. Outsourcing non-core functions like bioprocess development and manufacturing to contract manufacturing organizations (CMOs) has been a prominent trend that maximizes in-house R&D efficiencies for pharmaceutical companies. Leading CMOs employ standardized modular facilities based on single-use technologies to deliver commercial-grade production capabilities. Their ready-to-use, scalable resources, coupled with expert human resources, present a low-risk high-yield model for outsourcing. In turn, biopharmaceutical companies are able to bypass capital investments and focus on innovation instead of infrastructure development. The established quality systems at CMOs also inspire confidence in regulatory compliance.
Browse 35 Market Data Tables and 37 Figures spread through 165 Pages and in-depth TOC on Global Single-use Bioprocessing Systems Market, By Product Type (Bioreactors, Bags and Containers, Filtration Devices, Tubing Assemblies and Connectors, Sensors and Probes and Others (Accessories & Consumables, etc.)), By Application (Monoclonal Antibody Production, Vaccine Production, Cell Therapy, Viral Vector Production, Gene Therapy and Other Biopharmaceutical Production Processes), By End User (Biopharmaceutical Companies, CROs & CMOs and Others (Research Labs & Institutes, etc.)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Link: https://www.coherentmarketinsights.com/market-insight/single-use-bioprocessing-systems-market-1754
Key Developments:
- On May 25, 2024, MarqMetrix, one of the leaders in compositional analysis utilizing Raman spectroscopy, announced the launch of Single-Use BioReactor BallProbe. The Single-Use BioReactor BallProbe is crafted from sanitary-finished (15Ra) 316 stainless steel and features high-purity sapphire optics, meticulously designed to precisely fulfill the rigorous demands of the bioprocessing sector.
- On April 18, 2024, Cytiva, a provider of leading life sciences brands such as ÄKTA, Amersham, HyClone, MabSelect and Whatman launched X-platform bioreactors to simplify single-use upstream bioprocessing operations. X-platform bioreactors, initially available in 50 and 200 L sizes, are provided with Figurate automation solution software and can increase process efficiency through ergonomic improvements, production capability, and simplified supply chain operations.
- In October 2022, PharmNXT Biotech,a single use technology company based in Mumbai, India. launched its first integrated manufacturing unit to provide single-use bioprocessing solutions. The facility has been launched to address the challenges of biologics manufacturing in the country.
- In September 2021, Avantor, Inc., one of the leading global providers of mission-critical products and services to customers in the life sciences, advanced technologies & applied materials industries, announced that it had entered into a definitive agreement to acquire the Masterflex bioprocessing business, one of the leading global manufacturers of peristaltic pumps and aseptic single-use fluid transfer technologies.
Key Takeaways of the Global Single-use Bioprocessing Systems Market:
- The global single-use bioprocessing systems market is expected to exhibit a CAGR of 16.8% during the forecast period. For instance, in January 2020, 3i Group plc, a private equity and venture capital company announced that it had established a single use bioprocessing platform serving the biopharmaceutical sector with the acquisition of Cellon, a manufacturer of single-use products for bioprocessing, storage, and transport of sterile solutions for pharmaceutical and biotech companies in the production of biological drugs, vaccines, and therapies.
- Among regions, North America is expected to be the dominant region in the global single-use bioprocessing systems market due to increasing facility expansion by the key players. For instance, Thermo Fisher Scientific, a company specializing in analytical instruments, life sciences solutions and other services in April 2022, announced the opening of its new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies.
- Major players operating in the global single-use bioprocessing systems market include Merck KGaA, Thermo Fisher Scientific Inc., Liquidyne, Corning Incorporated, Foxx Life Sciences., PARKER HANNIFIN CORP, Danaher Corporation., Sartorius, GE Healthcare, Eppendorf, Getinge AB, PBS Biotech, Esco Bioengineering, Distek, Bionet and Other Prominent Players
